Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
about
CARs in chronic lymphocytic leukemia -- ready to driveGenetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on MelanomaModern Technologies for Creating Synthetic Antibodies for Clinical application.A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells.Engineered T cells for cancer treatmentImmunotherapy in acute leukemiaRedirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies.Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsVisualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer.Adoptive cellular immunotherapy for childhood malignancies.Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brainCharacterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.PET imaging of T cells derived from umbilical cord blood.Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunityTethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cellsEnhancing adoptive immunotherapy of cancer.Advances in the treatment of hematologic malignancies using immunoconjugatesCombination strategies to enhance antitumor ADCC.Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma.Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression.Imaging of T cells expressing chimeric antigen receptors.
P2860
Q26830526-755B86E6-77A7-4336-B8CD-060830F9CCC3Q27346600-08BF03B7-005A-4BDD-8FB3-BC91CF56DEC0Q30467308-9F09667A-5057-4280-A8E2-17C9460CBDEFQ30584839-0BD92F5B-C9C6-40DC-8149-85E804E805E7Q33578792-4CBACCE0-3A25-4E69-9320-16E0C3CE9536Q33731552-2966B959-B04B-4F8F-A678-F9432245F092Q34122292-F70EEB59-F2C0-4DE7-8132-B361BDD2FA9DQ34987908-4AAA4832-D75B-4EFC-9113-05A12C4633D4Q35670632-87B249B2-78DF-438F-B1E0-0E3FDF8498CDQ36453570-548E7D65-7362-464A-9B66-B65754237EF5Q36470354-E00FD734-1BDF-4061-A77F-12321BDA86F8Q36936395-B8ABD31E-4D32-499F-9A0D-FF47A67A4A80Q37008216-47F02246-2365-4681-8FD8-D8C512914C48Q37037932-A8E91BE7-AF00-44F0-B884-EF1998550A30Q37132892-21F2524A-1F5A-438C-B4A6-A2B8ED24F90BQ37412238-9DFD6A18-329F-449D-8D11-A22905CAC05FQ37469199-9FFC110C-99C5-417F-B421-CF39225D9151Q37474007-A298913A-7C54-4F57-9342-B817CF48CCECQ37687429-006D842C-B93C-4EAE-8F34-AA142B1B54F1Q37697843-5423F220-065E-4F1A-98FE-0C8609AD9C92Q38014085-7140FDD1-6782-4FB0-BEAD-9EF18A957039Q39375170-F21F7D05-9E17-4D7D-B968-FEDF7647B618Q39835934-0214AA20-3E0E-4924-9CDF-D955AE62AFEFQ53191013-FD7052EC-13B0-4044-BC2E-1012B38F8FC5
P2860
Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Combining adoptive cellular an ...... tment of B-lineage malignancy.
@en
type
label
Combining adoptive cellular an ...... tment of B-lineage malignancy.
@en
prefLabel
Combining adoptive cellular an ...... tment of B-lineage malignancy.
@en
P2093
P1433
P1476
Combining adoptive cellular an ...... tment of B-lineage malignancy.
@en
P2093
Andrew Raubitschek
David Colcher
George McNamara
Harjeet Singh
Laurence J N Cooper
Lisa Marie Serrano
Michael C Jensen
Simon Olivares
Stephen D Gillies
Stephen J Forman
P304
P356
10.1158/0008-5472.CAN-06-2283
P407
P577
2007-03-01T00:00:00Z